Related Experiment Video

Updated: Apr 9, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Antituberculosis drugs in children

H S Schaaf1, A J Garcia-Prats1, P R Donald1

  • 1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Clinical Pharmacology and Therapeutics
|June 23, 2015
PubMed

Insights

Pediatric tuberculosis (TB) requires better diagnosis and treatment. Understanding drug pharmacokinetics and pharmacodynamics is crucial for optimizing anti-TB drug dosing and developing child-friendly formulations to reduce childhood TB mortality.

Area of Science:

  • Pediatric infectious diseases
  • Pharmacology
  • Global health

Background:

  • Tuberculosis (TB) poses a significant global health risk to children, characterized by underdiagnosis and high rates of morbidity and mortality.
  • Effective management strategies include active contact tracing for preventive therapy and prompt diagnosis and treatment of both drug-susceptible and drug-resistant TB.

Purpose of the Study:

  • To review available antituberculosis drugs, focusing on their pharmacokinetic and pharmacodynamic properties in children.
  • To provide a rationale for current pediatric dosing recommendations for anti-TB drugs.
  • To highlight the need for further research to optimize pediatric TB treatment.

Main Methods:

  • Literature review of existing antituberculosis drugs.
  • Analysis of pharmacokinetic and pharmacodynamic data relevant to pediatric populations.
  • Discussion of current dosing strategies and knowledge gaps.

Main Results:

  • Limited pharmacokinetic data and few child-friendly formulations exist for pediatric anti-TB drugs.
  • Knowledge gaps persist regarding the pharmacodynamics of these drugs in children.
  • Current dosing recommendations are based on available, albeit limited, pediatric data.

Conclusions:

  • Optimizing the treatment of pediatric tuberculosis necessitates further pharmacokinetic and pharmacodynamic studies for both existing and novel anti-TB drugs.
  • Development of child-friendly formulations is essential for improving treatment adherence and outcomes in children.
  • Addressing these research needs is critical to reduce mortality and morbidity associated with childhood TB.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
903
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
738
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
383
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.5K